FIGURE 8 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Selinexor significantly enhances MYXV replication in PANC-1 xenograft tumors in NSG mice, reduces tumor burden and prolong survival. A, Diagram of experimental setup. NSG mice were inoculated with PANC-1 cells at day 0 via subcutaneous injection on both flanks. Animals received four doses of selinexor by oral gavage and three intratumoral injection of vMyx-FLuc on the right flank. Mice were imaged for luciferase activity 24 and 48 hours after first virus injection. B, Luminescence images taken using IVIS imaging system 24 and 72 hours after the first injection. C, Quantification of luminescence signals as relative light units (RLU) from images taken 24 and 72 hours after first injection. D–E, Tumor volumes on the left and the right flanks were measured at different days after the start of treatments. Results are presented as mean ± SEM. F, Kaplan–Meier survival curves comparing animals with different treatment groups. ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.